comprehensive -WSS

comprehensive

author：focus 2025-09-28 01:35:31 - browse：3

Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT — The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico.

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Illumina slashes 2023 revenue projections yet again

WSS

Surge in Apellis stock fueled by confidence in safety of its eye drug

Bacterial infection may be ‘key event’ in endometriosis, study says

When is a doctor not a doctor? Try when patients address women doctors

Be careful with at

Van's Gluten Free Original Waffles recalled for possible wheat allergen

What to know about the judge who will handle the Trump case

entertainment

comprehensive

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Inside the fall of star MIT scientist David Sabatini

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Senators push IRS to launch nonprofit hospital probe

In age of alternative facts, a scholarly course on calling out crap

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

In Memoriam: Notable people who died in 2023

Hospitals are dialing back on venture capital investing

Duchenne breakthrough therapy leaves behind pioneering families

New case study details death in closely watched Alzhiemer's trial

leisure time

Make 'food is medicine' a key part of White House nutrition meeting

Listen: Biogen's messy board & Laronde's data problem

Health AI: on the border between health care and tech

Option Care buys Amedisys in $3.6 billion home care deal

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Maui wildfire now ranks as the fifth

leisure time

knowledge

Wikipedia

hotspot